76 related articles for article (PubMed ID: 30237140)
1. Generation of induced pluripotent stem cell line (ZZUi007-A) from a 52-year-old patient with a novel CHCHD2 gene mutation in Parkinson's disease.
Wang Y; Wang Z; Sun H; Mao C; Yang J; Liu Y; Liu H; Zhang S; Zhang J; Xu Y; Shi C
Stem Cell Res; 2018 Oct; 32():87-90. PubMed ID: 30237140
[TBL] [Abstract][Full Text] [Related]
2. Generation of a human iPSC line from a Parkinson's disease patient with a novel CHCHD2 mutation (p.R145Q).
Chen X; Sun J; Wang T; Tang Q; Su L; Sun Y; Chen L; Seo H; Cheng T; Wang J; Song B
Stem Cell Res; 2024 Apr; 77():103419. PubMed ID: 38631182
[TBL] [Abstract][Full Text] [Related]
3. Generation of integration-free human induced pluripotent stem cells from a patient with sporadic Parkinson's disease.
Lee Y; Jeong D; Ham S; Son J; Ko K
Stem Cell Res; 2024 Apr; 77():103416. PubMed ID: 38615589
[TBL] [Abstract][Full Text] [Related]
4. Generation of TWO G51D SNCA missense mutation iPSC lines (CRICKi011-A, CRICKi012-A) from two individuals at risk of Parkinson's disease.
Devito LG; Zanjani ZS; Evans JR; Scardamaglia A; Houlden H; Gandhi S; Healy L
Stem Cell Res; 2023 Sep; 71():103134. PubMed ID: 37336145
[TBL] [Abstract][Full Text] [Related]
5. Development, characterization, and hematopoietic differentiation of Griscelli syndrome type 2 induced pluripotent stem cells.
Güney-Esken G; Erol ÖD; Pervin B; Gürhan Sevinç G; Önder T; Bilgiç E; Korkusuz P; Günel-Özcan A; Uçkan-Çetinkaya D; Aerts-Kaya F
Stem Cell Res Ther; 2021 May; 12(1):287. PubMed ID: 33985578
[TBL] [Abstract][Full Text] [Related]
6. Generation of induced pluripotent stem cells (ZZUCSBi001-A) from skin fibroblasts of a healthy donor.
Li SA; Zhang YJ; Zhu YQ; Meng XY; Chen CL; Liu PP; Sun W
Stem Cell Res; 2024 Apr; 76():103328. PubMed ID: 38335661
[TBL] [Abstract][Full Text] [Related]
7. Generation of induced pluripotent stem cells (NIMHi015-A) from a Parkinson's Disease patient harbouring a homozygous Exon 3 deletion in the PRKN gene.
Banerjee R; Ghanty R; Jagtap S; Holla V; Kamble N; Yadav R; Pal PK; Datta I
Stem Cell Res; 2024 May; 77():103440. PubMed ID: 38739971
[TBL] [Abstract][Full Text] [Related]
8. Induced pluripotent stem cell technology and direct conversion: new possibilities to study and treat Parkinson's disease.
Roessler R; Boddeke E; Copray S
Stem Cell Rev Rep; 2013 Aug; 9(4):505-13. PubMed ID: 22529017
[TBL] [Abstract][Full Text] [Related]
9. Generation of Leber congenital amaurosis, type 12 patient-specific induced pluripotent stem cell line (LVPEIi006-A), harboring a homozygous mutation in RD3.
Mahato S; Maddileti S; Naik M; Kannabiran C; Jalali S; Mariappan I
Stem Cell Res; 2024 Mar; 77():103380. PubMed ID: 38479331
[TBL] [Abstract][Full Text] [Related]
10. Generation and characterization of the iPS cell line (SYSUSHi001-A) derived from the peripheral blood mononuclear cells (PBMCs) of a 33-year-old patient with acute myeloid leukemia (AML).
Yuan L; Xie M; Tao Y; Chen X; Xu X; Wang X
Stem Cell Res; 2024 Feb; 77():103360. PubMed ID: 38608356
[TBL] [Abstract][Full Text] [Related]
11. CHCHD2 and CHCHD10 regulate mitochondrial dynamics and integrated stress response.
Ruan Y; Hu J; Che Y; Liu Y; Luo Z; Cheng J; Han Q; He H; Zhou Q
Cell Death Dis; 2022 Feb; 13(2):156. PubMed ID: 35173147
[TBL] [Abstract][Full Text] [Related]
12. Generation of an induced pluripotent stem cell line (KEIUi008-A) from a hearing loss patient with an A1555G mutation in mitochondrial DNA.
Masano Y; Saegusa C; Ishikawa M; Matsunaga T; Okano H; Fujioka M
Stem Cell Res; 2024 May; 78():103452. PubMed ID: 38815527
[TBL] [Abstract][Full Text] [Related]
13. Generation of a human induced pluripotent stem cell line (SHUPLi002-A) from PBMCs of a healthy female donor.
Li B; Ye X; Lin J; Ma K; He M; Fang Y
Stem Cell Res; 2024 Apr; 77():103422. PubMed ID: 38631181
[TBL] [Abstract][Full Text] [Related]
14. Biological implications and limitations of a cynomolgus monkey with naturally occurring Parkinson's disease.
Li H; Yao YG; Hu XT
Zool Res; 2021 Mar; 42(2):138-140. PubMed ID: 33554486
[TBL] [Abstract][Full Text] [Related]
15. Knockdown of CHCHD2 inhibits migration and angiogenesis of human renal cell carcinoma: A potential molecular marker for treatment of RCC.
Cheng Q; Qu D; Lu Z; Zhang L
Oncol Lett; 2019 Jan; 17(1):765-772. PubMed ID: 30655828
[TBL] [Abstract][Full Text] [Related]
16. Systematically analyzing rare variants of autosomal-dominant genes for sporadic Parkinson's disease in a Chinese cohort.
Yang N; Zhao Y; Liu Z; Zhang R; He Y; Zhou Y; Xu Q; Sun Q; Yan X; Guo J; Tang B
Neurobiol Aging; 2019 Apr; 76():215.e1-215.e7. PubMed ID: 30598256
[TBL] [Abstract][Full Text] [Related]
17. Early-onset Parkinson disease caused by a mutation in CHCHD2 and mitochondrial dysfunction.
Lee RG; Sedghi M; Salari M; Shearwood AJ; Stentenbach M; Kariminejad A; Goullee H; Rackham O; Laing NG; Tajsharghi H; Filipovska A
Neurol Genet; 2018 Oct; 4(5):e276. PubMed ID: 30338296
[TBL] [Abstract][Full Text] [Related]
18. Generation of an induced pluripotent stem cell (iPSC) line from a 42-year-old adult cerebral type X-linked adrenoleukodystrophy (X-ALD) patient.
Yeon GB; Son D; Kang PJ; Oh SM; Lim H; Kang HC; You S; Kim DS
Stem Cell Res; 2019 Apr; 36():101425. PubMed ID: 30921588
[TBL] [Abstract][Full Text] [Related]
19. Chchd2 regulates mitochondrial morphology by modulating the levels of Opa1.
Liu W; Duan X; Xu L; Shang W; Zhao J; Wang L; Li JC; Chen CH; Liu JP; Tong C
Cell Death Differ; 2020 Jun; 27(6):2014-2029. PubMed ID: 31907391
[TBL] [Abstract][Full Text] [Related]
20. Mutations in CHCHD2 cause α-synuclein aggregation.
Ikeda A; Nishioka K; Meng H; Takanashi M; Hasegawa I; Inoshita T; Shiba-Fukushima K; Li Y; Yoshino H; Mori A; Okuzumi A; Yamaguchi A; Nonaka R; Izawa N; Ishikawa KI; Saiki H; Morita M; Hasegawa M; Hasegawa K; Elahi M; Funayama M; Okano H; Akamatsu W; Imai Y; Hattori N
Hum Mol Genet; 2019 Dec; 28(23):3895-3911. PubMed ID: 31600778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
